Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 3 | 2015
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 1 | 2015
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States?
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of…
A New Era for Multiple Sclerosis Disease-Modifying Therapy: EU5 Prescriber and Payer Perspectives on Current Mainstays, Recent Market Entrants, and Late-Stage Pipeline Products | Physician & Payer Forum | EU5 | 2014
By February 2014, European marketing authorizations were granted for three new disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS)—Aubagio (Sanofi/Genzyme), Lemtrada (…
